PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, Steamboat Springs, Colorado. January 12-15, 2018

Transcription

1 PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 12-15, 2018 Friday, January 12, 2018 Registration: Begins at 6:30 am 6:50 pm Welcome Remarks Merrick I. Ross, MD Session I 7:00 am-8:45am Palliative Care Symposium Moderator: Brian D. Badgwell, MD How and When to Integrate the Palliative Care Team?* Sriram Yennu, MD Palliative Radiation for Bone Metastases* Quynh-Nhu Nguyen, MD Reducing the Use of Opiates: Impact on Cancer Related Outcomes* Thomas A. Aloia, MD Surgical Approaches to Symptomatic Lymphedema* Edward I-Fei Chang, MD Patient Reported Outcomes: How is This Information Used?* Thomas A. Aloia, MD Outcome-based Reimbursements in Cancer Care: Is This Just Around the Corner?* Karl Bilimoria, MD

2 Moderator: Brian D. Badgwell, MD Panel: All Speakers Session II 8:45 am-10:00 am HPV Symposium: From the Oris to the Anus Moderator: Erich M. Sturgis, MD HPV Head and Neck Cancer: Epidemiology and Outcomes Erich M. Sturgis, MD Vaccine Initiatives at Home and Abroad Kathleen M. Schmeler, MD Anal Cancer: Epidemiology and Evolving Treatment Paradigms Craig Messick, MD 10:00 am Noon Meet the Professor Session III 5:00 pm-8:30 pm Immunotherapy Symposium Moderator: Merrick I. Ross, MD Overview of Immunotherapy Across the Spectrum of Solid Tumors Sanjiv Agarwala, MD Combinations With Checkpoint Blockade: How to Make a Cold Tumor Hot T-Cell Activating Agents Patrick Hwu, MD Oncolytic (Intralesional) Agents Robert H. Andtbacka, MD

3 XRT: Can We Consistently Achieve an Abscopal Effect James Welsh, MD Combination With Targeted Therapies: Efficacy and Toxicity Diagnosing and Managing Immune-related and Targeted Therapy Toxicities Endocrine Dermatologic Joel Claveau, MD Opthalmologic Stella K. Kim, MD Biomarkers for Immunotherapy: How Useful are They Really? Welcome Reception: 8:30-9:30 pm Saturday, January 13, 2018 Session IV 7:00 am-9:30 am - Melanoma Moderator: Merrick I. Ross, MD Primary and Secondary Prevention Strategies Jeffrey E. Gershenwald, MD Completion Dissection in Patients With a Positive Sentinel Node: Is the Controversy Finally Resolved? Merrick I. Ross, MD

4 Optimal Front Line therapy for Disseminated Melanoma Huessein Tawbi, MD Adjuvant Therapy: Is There a Renewed Enthusiasm? Sanjiv S. Agarwala, MD Neo-adjuvant Approaches to Resectable Advanced Disease: Is This a New Paradigm? Merrick I. Ross, MD New Strategies in the Treatment of Brain Metastases: Are We Finally Making Progress? Michael Davies, MD Moderator: Merrick I. Ross, MD Panel: All Speakers; Victor G. Prieto, MD, PhD 10:00 am-noon - Meet the Professor Session V 4:30 pm-7:30 pm Thoracic Oncology Moderator: Stephen G. Swisher, MD Impact of Lung Cancer Screening Jeremy Erasmus, MD Checkpoint Blockage or Targeted Therapy for Advanced Lung Cancer: How to Decide John V. Heymach, MD, PhD Adjuvant or Neo Therapy for Resectable NSCLC: Are There Prospects for Targeted and/or Immunotherapy? John V. Heymach, MD, PhD Chemo-radiation for Advanced Esophageal Cancer: Front-line Results and the Role if Any for Salvage Surgery David C. Rice, MD

5 Minimally Invasive Approach to Early Esophageal Cancer Wayne L. Hofstetter, MD Results of Local Therapy for Oligometastatic NSCLC: Surgery or Radiation Therapy? Stephen G. Swisher, MD Moderator: Stephen G. Swisher, MD Panel: All Speakers Sunday, January 14, 2018 Session VI 7:00 am-9:30 am - Urology Moderator: Christopher G. Wood, MD Control of the Primary Tumor Improves Outcomes in Patients With Metastatic Prostate Cancer? Pro Brian F. Chapin, MD Con John W. Davis, MD Novel Systemic Therapy Options for Hormone Refractory Prostate Cancer Ana Aparicio, MD Update on Immunotherapy for Muscle Invasive Transitional Cell Carcinoma Neema Navai, MD Adrenocortical Carcinoma: Outcomes With Surgical and Systemic Therapy Jose A. Karam, MD Effectiveness and Toxicity of Pelvic Irradiation for Recurrent Prostate Cancer Andrew K. Lee, MD

6 What is the Optimal Management of the Small Renal Mass in 2018: Surveillance, Ablation, or Surgery? Active Surveillance Christopher G. Wood, MD Ablation R. Houston Thompson, MD Surgery Bradley C. Liebovich, MD Moderator: Christopher G. Wood, MD Panelists: All Speakers 10:00 am-noon - Meet the Professor Session VII 4:30 pm-7:30 pm GI Oncology Moderator: Robert A. Wolff, MD Any Translational Research Being Applied in Treating Pancreas Cancer? Jason B. Fleming, MD Definitive Radiation Therapy for Pancreas Cancer: Can This Replace Surgical Resection Christopher Crane, MD Molecular Biomarker Based Therapy for Colorectal Cancer: A New Standard of Care? Screening Initiatives for Hepato-cellular Cancer: Impace on Treatment Strategies and Results Decision Making in the Treatment of Liver Metastases from GI Malignancies Claudius Conrad, MD, PhD

7 Expanding the Indications for HIPEC? Brian Badgwell, MD Moderator: Robert A. Wolff, MD Panel: All Speakers Monday, January 15, 2018 Session VIII 7:00 am-10:30 am Breast Cancer Moderator: Kelly K. Hunt, MD Novel Approaches to SLN Biopsy After Neoadjuvant Therapy Abigail Caudle, MD Update on Neo-adjuvant Aromitase Inhibitor Strategies Kelly K. Hunt, MD Advances in the Treatment of Her-2 Positive Breast Cancer Mariana Chavez-McGregor, MD Any Progress Being Made in Triple Negative Breast Cancer? Jennifer Litton, MD Gene Expression Based Adjuvant Therapy: Results of Trials Mariana Chavez-McGregor, MD Adjuvant Radiation Therapy: Current Controversies George Perkins, MD Immunotherapy for Breast Cancer: Vaccines and Beyond Elizabeth Mittendorf, MD, PhD

8 Moderator: Kelly K. Hunt, MD Panel: All Speakers ADJOURNMENT *Presentations are appropriate for ethics credit